An observational study in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China — 29 open to participants now, 32 under way, 5 of them phase 3. Leukemia, Myeloid, Acute · Institute of Hematology & Blood Diseases Hospital, China.
Among the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 10 that started in 2026, is one of 5 observational ones, reaches primary completion later than 9 of the 31 other live ones, and was the 42nd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →29 of the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 55–75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 16 · Phase 3 5
First in 2005; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 30 across the 41 interventional studies, 169 across the 5 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
11 of the studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07132684Phase 3Institute of Hematology & Blood Diseases Hospital, ChinaComparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | 2027-08-30 |
| NCT06613035Phase 3Institute of Hematology & Blood Diseases Hospital, ChinaTwice-per-weekSelinexor, 2 Days Melphalan | 2027-09-30 |
| NCT06783790Institute of Hematology & Blood Diseases Hospital, ChinaAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | 2026-12 |
| NCT06635681Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | 2026-12-01 |
| NCT07441980Institute of Hematology & Blood Diseases Hospital, ChinaA Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective-prospective observational cohort study aims to evaluate peripheral blood plasma circulating tumor DNA (ctDNA) dynamics in pediatric acute leukemia and compare ctDNA results with concurrent bone marrow multiparameter flow cytometry minimal residual disease (MFC-MRD), droplet digital PCR (ddPCR), and RNA sequencing findings. The study includes a retrospective cohort with available clinical and molecular data and a prospective cohort with serially collected peripheral blood and bone marrow samples at predefined treatment time points. The study will assess consistence between plasma ctDNA and conventional bone marrow-based assays, characterize longitudinal ctDNA dynamics, and explore the association between ctDNA patterns and relapse or survival outcomes.
Minimal residual disease assessment is essential for treatment response evaluation and risk stratification in pediatric acute leukemia. Conventional MRD monitoring mainly relies on bone marrow-based assays, including multiparameter flow cytometry, molecular assays, and sequencing-based methods. However, repeated bone marrow sampling is invasive, and peripheral blood plasma ctDNA may provide a minimally invasive approach for dynamic disease monitoring.
This study will include pediatric patients with acute leukemia who have available peripheral blood plasma ctDNA testing data and corresponding clinical or molecular information. Existing clinical records, laboratory results, leukemia-related genetic findings, bone marrow MFC-MRD results, ddPCR results, RNA sequencing results, treatment information, and follow-up outcomes will be retrospectively collected. After study registration, follow-up outcomes and additional serial molecular monitoring data will be prospectively collected when available.
Peripheral blood plasma cfDNA/ctDNA results will be compared with matched or corresponding bone marrow-based assessments, including MFC-MRD, ddPCR, and RNA sequencing. The study will evaluate the concordance between plasma ctDNA and conventional bone marrow-based assays at different treatment time points, including diagnosis, pre-transplantation, post-transplantation, follow-up, and suspected relapse when available.
The study will further assess ctDNA clearance, persistence, or re-emergence during treatment and follow-up. Exploratory analyses will evaluate whether ctDNA dynamics are associated with treatment response, relapse, event-free survival, relapse-free survival, and overall survival.
Children were diagnosised with ALL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consistence between peripheral blood plasma ctDNA and bone marrow MFC-MRD
Concordance between peripheral blood plasma ctDNA status and matched bone marrow MFC-MRD results.
Time frame: From the date of enrollment to 6 months after hematopoietic stem cell transplantation, assessed up to 6 months post-transplantation.
Event-free survival
Time frame: The time from diagnosis to relapse, death from any cause, or last follow-up, whichever occurs first, assessed up to 36 months.
Overall survival
Time frame: From the date of diagnosis until the date of death from any cause or last follow-up, whichever occurs first, assessed up to 36 months.
ctDNA clearance rate
The rate of change of ctDNA positive to negative after stem cell transplantation.
Time frame: From the date of enrollment to 6 months after hematopoietic stem cell transplantation, assessed up to 6 months post-transplantation.
Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.
Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 11 months is below that.
Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Hematology & Blood Diseases Hospital, China →